Catalyst Wire Dossier Catalyst Wire Dossier

Nabulimab

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nabulimab, covering 2024-11-08 to 2024-11-08. Get the full timeline:

Most recent: Clinical Trial Update: A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab [Phase 2]

See pricing